

methylphenoxy)ethyl](dimethyl)ammonio}methyl hydrogen phosphate.

17. A pharmaceutical composition comprising the compound according to claim 1, or an addition salt thereof with a pharmaceutically acceptable acid or base, in combination with one or more pharmaceutically acceptable excipients.
18. The use of an effective amount of the compound according to claim 1, alone or in combination with one or more pharmaceutically acceptable excipients, in the treatment of a condition requiring a pro-apoptotic agent in a subject in need.
19. The use according to claim 18, wherein the condition is selected from cancer, autoimmune diseases and immune system diseases.
20. The use according to claim 19, wherein the condition is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
21. A combination of the compound according to claim 1, with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors and antibodies.
22. A pharmaceutical composition comprising the combination according to claim 21 in combination with one or more pharmaceutically acceptable excipients.
23. The use of an effective amount of the combination according to Claim 21, alone or in combination with one or more pharmaceutically acceptable excipients, in the treatment of cancer in a subject in need.
24. The use of an effective amount of the combination according to Claim 3, alone or in combination with one or more pharmaceutically acceptable excipients, in the treatment

of cancer in a subject in need.